PT3270890T - Formulações de ciclosporina para utilização na prevenção ou tratamento de rejeição crónica de enxerto pulmonar - Google Patents

Formulações de ciclosporina para utilização na prevenção ou tratamento de rejeição crónica de enxerto pulmonar

Info

Publication number
PT3270890T
PT3270890T PT167115658T PT16711565T PT3270890T PT 3270890 T PT3270890 T PT 3270890T PT 167115658 T PT167115658 T PT 167115658T PT 16711565 T PT16711565 T PT 16711565T PT 3270890 T PT3270890 T PT 3270890T
Authority
PT
Portugal
Prior art keywords
prevention
treatment
graft rejection
chronic graft
cyclosporine formulations
Prior art date
Application number
PT167115658T
Other languages
English (en)
Original Assignee
Breath Therapeutics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Breath Therapeutics Gmbh filed Critical Breath Therapeutics Gmbh
Publication of PT3270890T publication Critical patent/PT3270890T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13Cyclosporins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Otolaryngology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT167115658T 2015-03-16 2016-03-15 Formulações de ciclosporina para utilização na prevenção ou tratamento de rejeição crónica de enxerto pulmonar PT3270890T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15020035.0A EP3069711A1 (en) 2015-03-16 2015-03-16 Cyclosporine formulations for use in the prevention or treatment of pulmonary chronic graft rejection

Publications (1)

Publication Number Publication Date
PT3270890T true PT3270890T (pt) 2023-11-27

Family

ID=52686066

Family Applications (1)

Application Number Title Priority Date Filing Date
PT167115658T PT3270890T (pt) 2015-03-16 2016-03-15 Formulações de ciclosporina para utilização na prevenção ou tratamento de rejeição crónica de enxerto pulmonar

Country Status (16)

Country Link
US (3) US10857198B2 (pt)
EP (2) EP3069711A1 (pt)
AU (1) AU2016232307B2 (pt)
CA (1) CA2979498C (pt)
DK (1) DK3270890T3 (pt)
ES (1) ES2964789T3 (pt)
FI (1) FI3270890T3 (pt)
HR (1) HRP20231621T1 (pt)
HU (1) HUE064422T2 (pt)
LT (1) LT3270890T (pt)
PL (1) PL3270890T3 (pt)
PT (1) PT3270890T (pt)
RS (1) RS64884B1 (pt)
SI (1) SI3270890T1 (pt)
SM (1) SMT202300434T1 (pt)
WO (1) WO2016146645A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3069711A1 (en) * 2015-03-16 2016-09-21 PARI Pharma GmbH Cyclosporine formulations for use in the prevention or treatment of pulmonary chronic graft rejection
EP3773664B1 (en) 2018-04-11 2024-05-01 Breath Therapeutics GmbH Cyclosporine formulations for use in the treatment of bronchiolitis obliterans syndrome (bos)
EA202092893A1 (ru) 2018-06-27 2021-04-19 Брес Терапьютикс Гмбх Фармацевтические композиции в лиофилизированной форме
JP7526103B2 (ja) * 2018-06-27 2024-07-31 ブレス テラポイティクス ゲーエムベーハー 大環状免疫抑制剤を含む吸入用組成物
EA202092892A1 (ru) * 2018-12-04 2021-05-27 Брес Терапьютикс Гмбх Ингаляционные композиции, содержащие макроциклические иммуносупрессанты
WO2021130170A1 (en) * 2019-12-23 2021-07-01 Zambon S.P.A. Process for the preparation of dispersions comprising inhalable immunosuppressive active ingredients

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020006901A1 (en) * 1999-02-05 2002-01-17 Aldo T. Iacono Use of aerosolized cyclosporine for prevention and treatment of pulmonary disease
WO2003035030A1 (en) 2001-10-24 2003-05-01 Pari Gmbh Kit for the preparation of a pharmaceutical composition
DE102006051512A1 (de) * 2005-12-06 2007-06-14 Pari GmbH Spezialisten für effektive Inhalation Pharmazeutische Medikamentenzusammensetzungen mit Cyclosporin
EP2525854A1 (en) * 2010-01-20 2012-11-28 Koninklijke Philips Electronics N.V. Method of using a temperature-based aerosol detector
EP3069711A1 (en) * 2015-03-16 2016-09-21 PARI Pharma GmbH Cyclosporine formulations for use in the prevention or treatment of pulmonary chronic graft rejection
EP3773664B1 (en) * 2018-04-11 2024-05-01 Breath Therapeutics GmbH Cyclosporine formulations for use in the treatment of bronchiolitis obliterans syndrome (bos)
EA202092892A1 (ru) * 2018-12-04 2021-05-27 Брес Терапьютикс Гмбх Ингаляционные композиции, содержащие макроциклические иммуносупрессанты

Also Published As

Publication number Publication date
HRP20231621T1 (hr) 2024-03-15
SMT202300434T1 (it) 2024-01-10
SI3270890T1 (sl) 2024-02-29
EP3270890B1 (en) 2023-09-13
LT3270890T (lt) 2023-12-11
BR112017018339A2 (pt) 2018-04-17
CA2979498A1 (en) 2016-09-22
PL3270890T3 (pl) 2024-03-04
AU2016232307A1 (en) 2017-08-17
EP3270890A1 (en) 2018-01-24
CA2979498C (en) 2021-09-07
DK3270890T3 (da) 2023-12-11
ES2964789T3 (es) 2024-04-09
AU2016232307B2 (en) 2019-04-18
US11744872B2 (en) 2023-09-05
HUE064422T2 (hu) 2024-03-28
US10857198B2 (en) 2020-12-08
WO2016146645A1 (en) 2016-09-22
EP3069711A1 (en) 2016-09-21
US20240016885A1 (en) 2024-01-18
FI3270890T3 (fi) 2023-12-05
RS64884B1 (sr) 2023-12-29
US20180042988A1 (en) 2018-02-15
US20210046150A1 (en) 2021-02-18

Similar Documents

Publication Publication Date Title
GB2548873B (en) Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
IL290150A (en) Compounds and methods for treating chronic pain
GB201411496D0 (en) Use of 7-Oh-Cannabidiol (7-Oh-CBD) and/or 7-Oh-Cannabidvarin (7-Oh-CBDV) in the treatment of epilepsy
ZA201707303B (en) Compositions and methods for the treatment of immunodeficiency
PL3297628T3 (pl) Azasetron do stosowania w leczeniu niedosłuchu
SI3270890T1 (sl) Ciklosporinske formulacije za uporabo pri preprečevanju ali zdravljenju pljučne kronične zavrnitve presadka
IL258139A (en) Nicotine compositions and methods for their preparation and use
PL3113778T3 (pl) Pochodne pirydazyny do stosowania w zapobieganiu lub leczeniu zaburzenia ataktycznego
IL270701A (en) Neurotrophins for use in the treatment of hearing loss
HUS2400045I1 (hu) Delgocitinib alkalmazása krónikus kézekcéma kezelésére
LT3373922T (lt) Kompozicijos ir būdai skirti naudoti homocistinurijos gydyme
HUE067036T2 (hu) 2-hidroxibenzilamin alkalmazása pulmonális magas vérnyomás kezelésében és megelõzésében
PL3320901T3 (pl) Dimetyloaminomicheliolid do zastosowania w leczeniu włóknienia płuc
SI3197556T1 (sl) Sestavek za preprečevanje in/ali zdravljenje alergijskih simptomov
PL3675879T3 (pl) Cerebrolizyna do zastosowania w leczeniu cadasil
HUE066511T2 (hu) Készítmények hunter-szindróma kezelésére
IL257689B (en) Pharmaceutical preparations and methods for treating diseases related to lack of oxygen
GB201511772D0 (en) Improvements in the treatment of ash
PH32016000630S1 (en) Game chair
PH32016000629S1 (en) Game chair
PH32016000626S1 (en) Gaming chair
PH32016000624S1 (en) Gaming chair
PH32016000625S1 (en) Gaming chair
LT3297628T (lt) Azasetronas, skirtas naudoti klausos praradimo gydymui
HK1248110A1 (en) Plx-8394 or plx-7904 for use in the treatment of braf-v600-related diseases